title: Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs.
abstract: More active and well-tolerated agents are needed for the treatment of superficial bladder cancer. This study investigated intravesical gemcitabine to establish the toxicology and pharmacokinetics necessary for clinical trials. Beagle dogs (in groups of 2; n = 6) received 100 mg, 350 mg, or 1 g of drug by intravesical administration on alternate days three times/week for 4 weeks. Animals were observed for clinical signs of toxicity; gemcitabine levels and peripheral blood counts were taken three times weekly. The dogs were euthanized, and a full necropsy was performed at days 1 and 14 after the last dose. Intravesical gemcitabine was given at 100 mg (n = 2), 350 mg (equivalent to the 1000 mg/m2 human dose; n = 3), and 3.5 g (n = 1). i.v. gemcitabine was given at 350 mg (n = 2). Plasma samples drawn at time points up to 8 h were analyzed for systemic absorption and clearance of drug. Doses of 100 and 350 mg were well tolerated with no clinical side effects. Necropsies revealed normal bone marrow cellularity and normal bladder histology. At 1 g, signs of severe clinical toxicity were evident, and after only three doses, necropsies demonstrated severe bone marrow hypoplasia, cystitis, and intestinal necrosis. At all intravesical doses, significant systemic absorption was seen. The T1/2 (+/- SD) for intravesical and i.v. administration of 350 mg was 328 (+/-6.8) min and 99.3 (+/-5.2) min, respectively (P<0.001). Intravesical gemcitabine is well tolerated and has no direct bladder toxicity at doses up to 1000 mg/m2. Higher doses result in gastrointestinal, bladder, and bone marrow toxicity.
authors.affiliation: Urology Service, The George M. O'Brien Urology Research Center, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
authors.forename: P J
authors.initials: PJ
authors.lastname: Cozzi
authors.forename: D F
authors.initials: DF
authors.lastname: Bajorin
authors.forename: W
authors.initials: W
authors.lastname: Tong
authors.forename: H
authors.initials: H
authors.lastname: Nguyen
authors.forename: J
authors.initials: J
authors.lastname: Scott
authors.forename: W D
authors.initials: WD
authors.lastname: Heston
authors.forename: G
authors.initials: G
authors.lastname: Dalbagni
mesh_terms: D000042:Absorption; D000283:Administration, Intravesical; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000097:blood / Q000493:pharmacokinetics* / Q000633:toxicity* / Q000652:urine; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics / Q000633:toxicity / Q000652:urine; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007262:Infusions, Intravenous; D001743:Urinary Bladder / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine